Following recent concern that the hypoglycemic agent rosiglitazone might increase the already elevated risk of myocardial infarction in patients with type 2 diabetes, Home et al. conducted an ...

Objective: Published reports suggest that pioglitazone and rosiglitazone have different effects on lipids in patients with type 2 diabetes. However, these previous studies were either ...

A trial in which rosiglitazone and glipizide were compared supports earlier findings that rosiglitazone does not have an adverse effect on the progression of coronary atherosclerosis ...

Conclusions EHF decreased the sensitivity of PC to the stimulus from PSC-derived CSC-supportive niche by negatively regulating tumorous CXCR4. Rosiglitazone could be used to target PC stem cells and ...

Rosiglitazone, a drug from the thiazolidinedione class, has been used to help control blood sugar levels in people with type 2 diabetes. However, a recent study from the Yale School of Public ...

‘Peroxisome proliferator-activated receptor-gamma’ (PPARg), a transcription factor drugable by anti-diabetic insulin sensitizers (pio- and rosiglitazone), attenuates RAS-signaling and is itself ...

Data Synthesis: Studies of glyburide and glipizide have found little or no transfer of these drugs across the placenta, whereas metformin and rosiglitazone cross readily. Animal studies have found ...